Evidence map›Paper›PMID 41979184›Full record

ArticleClinical and translational science2026

When Selectivity Increases Uncertainty: Context-Dependent Pharmacology in Antibody Drug Development.

Xiaozhi Liao, Yanguang Cao

Abstract read
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiaozhi LiaoDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel, USA.ORCID 0000-0002-9925-5892
Yanguang CaoDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel, USA.ORCID 0000-0002-3974-9073

Funding

Quantitative Systems Pharmacology of Antibody Therapeutics across Diverse Biological ContextsR35GM152449 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Yanguang Cao · 2024 to 2026
$1.2M
NIGMS NIH HHS R35 GM152449
6 · The paper itself

Abstract

As antibody therapeutics become increasingly selective and multi-specific, their pharmacological effects depend more strongly on biological context, creating new uncertainties in drug development. In this perspective, we discuss how context-dependent pharmacology complicates preclinical-to-clinical translation, dose optimization, and rational combination therapy selection for antibody drugs. Recognizing context dependence is essential for realizing the full therapeutic potential of highly selective biologics and for advancing a more predictive, mechanism-informed paradigm in antibody drug development.

Indexed as

Antibodies, MonoclonalDrug DevelopmentAnimalsHumansUncertaintyAntibodies, Monoclonal

Identifiers

PMID41979184
PMCPMC13077777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.